Primary Treatment of Macroglobulinemic Lymphoma With 2CdA [cladribine], Cyclophosphamide and Rituximab.

Trial Profile

Primary Treatment of Macroglobulinemic Lymphoma With 2CdA [cladribine], Cyclophosphamide and Rituximab.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Cladribine (Primary) ; Cyclophosphamide (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Sep 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
    • 08 Sep 2015 Planned primary end date changed from 1 Jul 2015 to 1 Jul 2017 as reported by ClinicalTrials.gov record.
    • 09 Sep 2013 Planned end date changed from 1 Jul 2014 to 1 Jul 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top